This is the authors' abstract. We don't add key points for this paper.
Imaging procedures based on small molecule-radio conjugates (SMRCs) targeting fibroblast activation protein (FAP) have recently emerged as a powerful tool for the diagnosis of a wide variety of tumours. However, the therapeutic potential of radiolabeled FAP-targeting agents is limited by their short residence time in neoplastic lesions. In this work, we present the development and in vivo characterization of BiOncoFAP, a new dimeric FAP-binding motif with extended tumour residence time and favorable tumour-to-organ ratio. Methods: The binding properties of BiOncoFAP and its monovalent OncoFAP analogue were assayed against recombinant hFAP. Preclinical experiments with [¹⁷⁷Lu]Lu-OncoFAP-DOTAGA (¹⁷⁷Lu-OncoFAP) and [¹⁷⁷Lu]Lu-BiOncoFAP-DOTAGA (¹⁷⁷Lu-BiOncoFAP) were performed in mice bearing FAP-positive HT-1080 tumours. Results: OncoFAP and BiOncoFAP displayed comparable sub-nanomolar dissociation constants towards hFAP in solution, but the bivalent BiOncoFAP bound more avidly to the target immobilized on solid supports. In a comparative biodistribution study, ¹⁷⁷Lu-BiOncoFAP exhibited a more stable and prolonged tumour uptake than ¹⁷⁷Lu-OncoFAP (~20% ID/g vs ~4% ID/g, at 24h p.i., respectively). Notably, ¹⁷⁷Lu-BiOncoFAP showed favorable tumour-to-organ ratios with low kidney uptake. Both ¹⁷⁷Lu-OncoFAP and ¹⁷⁷Lu-BiOncoFAP displayed potent anti-tumour efficacy when administered at therapeutic doses in tumour bearing mice. Conclusion:¹⁷⁷Lu-BiOncoFAP is a promising candidate for radioligand therapy of cancer, with favorable in vivo tumour-to-organ ratio, long tumour residence time and potent anti-cancer efficacy.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Galbiati et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: